GLENMARK PHARMACEUTICALS Stock Context for AI Screening

GLENMARK PHARMACEUTICALS is a mid-cap stock in Healthcare. This page summarizes key screening signals for GLENMARK PHARMACEUTICALS, including recent returns, momentum indicators, valuation ratios, liquidity, and growth metrics. Gimli uses this context to help users ask natural-language stock screening questions across Indian equities.

Open interactive GLENMARK stock page

Price

₹2,223.70

1W return

+2.86%

1M return

+2.17%

3M return

+2.31%

6M return

+6.92%

1Y return

+21.48%

Market cap

₹62,752.99 cr

46.08

5.97

ROE

+14.07%

ROCE

+19.56%

RSI

51.47

Turnover

₹75.00 cr

Why it can matter in screens

Momentum: GLENMARK is above 200DMA; RSI is 51.47.
Returns: 1D -1.82%, 1W +2.86%, 1M +2.17%, 3M +2.31%, 1Y +21.48%.
Trend levels: 52W high ₹2,417.90, 52W low ₹1,810.40, off high -8.03%.
Liquidity: latest turnover is ₹75.00 cr; volume vs 20D is +0.57%.
Valuation/profitability: PE 46.08, PB 5.97, ROE +14.07%, ROCE +19.56%.
Growth: 3Y sales CAGR +13.49%, 3Y profit CAGR +66.07%.

Financials and Ownership

Quarterly income statement

Period	Revenue	EBITDA	PAT	EPS
2026-03-31	3,760.28 cr	578.28 cr	301.41 cr	10.68
2025-12-31	3,888.00 cr	729.88 cr	403.21 cr	14.29
2025-09-30	6,003.79 cr	1,175.06 cr	610.35 cr	21.63
2025-06-30	3,059.33 cr	283.73 cr	46.87 cr	1.66
2025-03-31	3,220.13 cr	199.89 cr	4.65 cr	0.16
2024-12-31	3,301.90 cr	631.36 cr	347.96 cr	12.33
2024-09-30	3,400.50 cr	641.33 cr	n/a	nan
2024-06-30	3,223.30 cr	619.71 cr	340.27 cr	12.06

Annual income statement

Year	Revenue	EBITDA	PAT	EPS
2026-03-31	16,711.40 cr	2,766.95 cr	1,361.85 cr	48.26
2025-03-31	13,145.84 cr	2,092.28 cr	1,047.10 cr	37.11
2024-03-31	11,635.46 cr	1,183.27 cr	-1,501.67 cr	-53.22
2023-03-31	11,431.94 cr	1,200.15 cr	297.25 cr	10.53
2022-03-31	8,756.21 cr	2,226.06 cr	1,997.79 cr	70.80

Balance sheet

Period	Assets	Cash	Debt	Equity
2026-03-31	19,907.88 cr	1,174.71 cr	593.53 cr	10,511.79 cr
2025-03-31	16,049.55 cr	1,675.71 cr	2,472.67 cr	8,849.07 cr
2024-03-31	14,358.62 cr	1,658.27 cr	1,230.93 cr	7,847.55 cr
2023-03-31	19,371.68 cr	1,159.20 cr	4,607.88 cr	9,839.26 cr
2022-03-31	17,083.29 cr	1,410.53 cr	3,962.02 cr	9,438.12 cr

Cash flow

Period	OCF	FCF	Cash change
2026-03-31	3,445.03 cr	2,087.32 cr	n/a
2025-03-31	-827.60 cr	-1,578.32 cr	n/a
2024-03-31	-265.44 cr	-1,163.82 cr	n/a
2023-03-31	625.39 cr	17.63 cr	n/a
2022-03-31	1,108.65 cr	318.54 cr	n/a

Shareholding Trend

Period	Promoter	FII/FPI	DII	MF	Retail	Pledge
2026-03-31	+46.65%	+20.34%	+19.29%	+16.80%	+13.68%	+0.00%
2025-12-31	+46.65%	+19.20%	+20.09%	+17.86%	+14.02%	+0.00%
2025-09-30	+46.65%	+20.73%	+18.61%	+16.31%	+13.97%	+0.00%
2025-06-30	+46.65%	+20.62%	+17.64%	+15.55%	+15.06%	+0.00%
2025-03-31	+46.65%	+23.16%	+14.60%	+12.86%	+15.56%	+0.00%

Industry Peers

Symbol	Name	Mcap	PE	ROE	1Y
SUNPHARMA	SUN PHARMACEUTICAL IND L	453,042.43 cr	39.400236	+14.71%	+12.90%
DIVISLAB	DIVI S LABORATORIES LTD	179,324.04 cr	69.830233	+16.19%	-2.64%
TORNTPHARM	TORRENT PHARMACEUTICALS L	164,701.07 cr	76.144739	+17.18%	+46.47%
APOLLOHOSP	APOLLO HOSPITALS ENTER. L	125,861.94 cr	64.267738	+21.03%	+15.71%
CIPLA	CIPLA LTD	115,660.88 cr	29.801362	+11.79%	-3.80%
ZYDUSLIFE	ZYDUS LIFESCIENCES LTD	115,515.66 cr	23.036787	+17.93%	+16.76%
LUPIN	LUPIN LIMITED	112,429.39 cr	21.054508	+26.83%	+27.93%
DRREDDY	DR. REDDY S LABORATORIES	112,317.04 cr	26.207396	+11.94%	+5.08%

Try these prompts

Analyze GLENMARK PHARMACEUTICALS with valuation, momentum and industry peers
Compare GLENMARK with other Healthcare stocks
Show mid-cap stocks in Healthcare above 50DMA with positive 1M return
Find Healthcare stocks with improving momentum and reasonable valuation

Related screen ideas

Data snapshot: 2026-07-08. Not investment advice.